Advertisement
EYPT vs KROS
Which Stock Would AI Choose? EyePoint Pharmaceuticals (EYPT) vs. Keros Therapeutics (KROS) Stock Comparison
Key Takeaways
- EYPT (EyePoint Pharmaceuticals) suffered a major clinical setback when its lead candidate DURAVYU failed a second Phase 3 trial, triggering a roughly 53% workforce reduction and a sharp repricing of the stock.
- KROS (Keros Therapeutics) is executing on a partnership-backed pipeline, recently adding a $20 million milestone payment from Takeda, but still has no marketed product and no recurring revenue.
- Both companies are clinical-stage biotechs with binary, trial-driven risk profiles, but they differ sharply in cash runway, strategic flexibility, and recent momentum.
- EYPT has pivoted its remaining resources toward diabetic macular edema (DME), while KROS is advancing rinvatercept in Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
- Analyst sentiment has deteriorated for EYPT after multiple downgrades, whereas KROS retains a more balanced mix of Buy and Hold ratings despite a weak year-to-date share performance.
Introduction
Investors evaluating speculative biotech opportunities often weigh companies with very different risk profiles against one another. EYPT and KROS both belong to the clinical-stage biotechnology segment, yet recent events have pushed them onto divergent paths. This stock comparison is most relevant for traders and investors who follow catalyst-driven names, monitor clinical trial readouts, and seek to understand how market positioning and relative performance shift after major news. Both tickers carry the elevated volatility typical of pre-revenue drug developers, making an objective review of their business models, momentum, and risk factors essential before forming any view.
EYPT Overview and Recent Performance
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on sustained-release treatments for serious retinal diseases. Its lead candidate, DURAVYU, is a bioerodible intravitreal insert designed to deliver medication over roughly six months and reduce treatment burden for patients with conditions such as diabetic macular edema (DME).
Recent market activity has been dominated by a significant negative catalyst. In recent weeks, DURAVYU failed to meet the primary endpoint in a second Phase 3 study for wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. While the drug demonstrated some clinical benefits, it did not match the efficacy of the standard-of-care comparator. In response, the company announced plans to cut approximately 53% of its workforce, halt its wet AMD program, and refocus capital on DME, where two Phase 3 trials are ongoing.
The market reaction was severe, with the stock falling sharply to historic lows. Multiple sell-side firms subsequently issued downgrades and reduced price targets, reflecting reduced confidence in the remaining pipeline. As of its most recent disclosure, EyePoint reported roughly $118 million in cash and investments, which management believes supports operations toward the late-2027 DME readouts. Sentiment has turned decidedly cautious as investors reassess the probability of success for a repurposed program.
KROS Overview and Recent Performance
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics targeting the TGF-beta family of proteins, which regulate the growth, repair, and maintenance of tissues including muscle, bone, and blood. Its lead wholly owned candidate, rinvatercept, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). Its most advanced program, elritercept, is partnered with Takeda for the treatment of cytopenias such as anemia and thrombocytopenia.
In recent weeks, Keros announced a $20 million development milestone from Takeda triggered by first-patient dosing in a Phase 3 study of elritercept, adding near-term financial flexibility. However, the company still has no marketed products and reported no product revenue in the second quarter of 2026, underscoring its dependence on collaboration-related income. Cash and equivalents stood at roughly $257.6 million as of June 30, 2026, with a runway expected to fund operations into the first half of 2028.
Despite this stability, KROS shares have declined materially year to date, underperforming the broader biotech industry. The stock carries a mixed analyst profile, with several Buy ratings alongside Hold ratings. The key catalyst ahead is initial Phase 2 data for rinvatercept in DMD, anticipated in the first half of 2027.
Trending AI Robots
For traders seeking a systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of different tickers, each with its own trading style, timeframe, performance record, and set of statistics. Because not every bot suits every market condition, the platform surfaces only those currently demonstrating the strongest alignment with prevailing market dynamics in this featured section. Investors can explore bots spanning varied strategies and risk profiles to identify approaches that match their own objectives. Browsing the Trending AI Robots selection is a practical starting point for understanding how AI-driven models are positioning across volatile, catalyst-heavy equities.
Head-to-Head Comparison
The two companies contrast most sharply in strategic stability. EYPT is in active restructuring mode after a decisive clinical failure, with a sharply reduced valuation and a single-asset focus on DME. KROS, by contrast, maintains a more diversified pipeline and a partner-funded late-stage program, offering multiple shots on goal.
On financial footing, KROS holds a larger cash balance and a longer runway, reducing near-term dilution risk relative to EYPT. However, KROS also lacks recurring revenue and depends on irregular milestone payments, whereas EYPT's challenge is the opposite: a smaller cash base now dedicated almost entirely to one remaining indication.
From a momentum and sentiment standpoint, both stocks have declined over the trailing period, but for different reasons. EYPT's drop reflects a fundamental reassessment of its lead program's viability. KROS's weakness appears tied to pre-commercial revenue volatility and broader biotech pressure rather than a single clinical failure. Risk factors also differ: EYPT faces execution and financing risk concentrated in DME, while KROS faces competitive pressure in DMD and milestone-timing uncertainty.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view KROS as the comparatively more stable candidate in the current environment. Its larger cash runway, partner-funded late-stage asset, and multi-indication pipeline suggest more consistent fundamentals, even amid weak recent price performance. EYPT, while now trading at a sharply reduced valuation, presents a higher-risk, higher-uncertainty profile following a failed pivotal trial and a major restructuring. A probabilistic model would likely assign KROS a more favorable relative positioning on stability and catalyst diversity, while noting that EYPT's depressed valuation could attract momentum-driven interest if sentiment stabilizes. The ultimate signal depends on each bot's specific strategy and timeframe.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and KROS is a StrongBuy.
EYPT's Indicator enters downward trend
The Aroon Indicator for EYPT entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 330 similar instances where the Aroon Indicator formed such a pattern. In 300 of the 330 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EYPT as a result. In 59 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for EYPT turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in 247 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
EYPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.222) is normal, around the industry mean (2.973). P/E Ratio (-0.114) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (101.010) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. EYPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KROS sees its Stochastic Oscillator ascending out of oversold territory
On October 21, 2026, the Stochastic Oscillator for KROS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 49 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
KROS moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 227 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 193 of 226 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 76 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 29 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.858) is normal, around the industry mean (2.973). P/E Ratio (-3.525) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EYPT | KROS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 95 | |
PRICE GROWTH RATING 1..100 | 99 | 57 | |
P/E GROWTH RATING 1..100 | 5 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 35 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (27) in the null industry is somewhat better than the same rating for EYPT (64) in the Pharmaceuticals Major industry. This means that KROS’s stock grew somewhat faster than EYPT’s over the last 12 months.
KROS's Profit vs Risk Rating (100) in the null industry is in the same range as EYPT (100) in the Pharmaceuticals Major industry. This means that KROS’s stock grew similarly to EYPT’s over the last 12 months.
KROS's SMR Rating (95) in the null industry is in the same range as EYPT (99) in the Pharmaceuticals Major industry. This means that KROS’s stock grew similarly to EYPT’s over the last 12 months.
KROS's Price Growth Rating (57) in the null industry is somewhat better than the same rating for EYPT (99) in the Pharmaceuticals Major industry. This means that KROS’s stock grew somewhat faster than EYPT’s over the last 12 months.
EYPT's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for KROS (97) in the null industry. This means that EYPT’s stock grew significantly faster than KROS’s over the last 12 months.
| EYPT | KROS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | N/A |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Advances ODDS (%) | 15 days ago 84% | 3 days ago 77% |
| Declines ODDS (%) | 3 days ago 88% | 9 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EYPT’s FA Score shows that 1 FA rating(s) are green while KROS’s FA Score has 1 green FA rating(s).
- EYPT’s FA Score: 1 green, 4 red.
- KROS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EYPT’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).
- EYPT’s TA Score: 4 bullish, 4 bearish.
- KROS’s TA Score: 5 bullish, 3 bearish.
Price Growth
EYPT (@Biotechnology) experienced а -86.37% price change this week, while KROS (@Biotechnology) price change was +2.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
EYPT is expected to report earnings on Nov 04, 2026.
KROS is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EYPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with ATHE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then ATHE could also see price increases.
| Ticker / NAME | Correlation To EYPT | 1D Price Change % | ||
|---|---|---|---|---|
| EYPT | 100% | -0.44% | ||
| ATHE - EYPT | 54% Loosely correlated | -10.04% | ||
| KROS - EYPT | 40% Loosely correlated | +1.52% | ||
| AMLX - EYPT | 38% Loosely correlated | -1.58% | ||
| KYTX - EYPT | 37% Loosely correlated | -1.88% | ||
| VTGN - EYPT | 37% Loosely correlated | -3.41% | ||
More | ||||
KROS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | +1.52% | ||
| SANA - KROS | 48% Loosely correlated | +0.85% | ||
| ABEO - KROS | 44% Loosely correlated | -0.89% | ||
| AXON - KROS | 43% Loosely correlated | +2.98% | ||
| EDIT - KROS | 43% Loosely correlated | -0.80% | ||
| TSHA - KROS | 43% Loosely correlated | -2.79% | ||
More | ||||